8-K: ArriVent BioPharma Reports Strong Interim Phase 1b Data for Firmonertinib in NSCLC, Advances to Pivotal Global Study

ArriVent BioPharma, Inc. announced positive interim data from its global Phase 1b study of firmonertinib monotherapy in EGFR PACC mutant non-small cell lung cancer, leading to plans for a global pivotal Phase 3 study.

Summary

• ArriVent BioPharma, Inc. announced positive interim data from its global Phase 1b FURTHER trial for firmonertinib monotherapy in first-line non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations.
• Patients treated with 240 mg of firmonertinib achieved a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months by blinded independent central review (BICR) as of March 3, 2025.
• The overall response rate (ORR) was 68.2% for patients treated at 240 mg and 43.5% at 160 mg.
• Significant central nervous system (CNS) activity was observed, with 41% (7/17) of first-line patients with brain metastases experiencing a confirmed response and 53% (9/17) experiencing at least a 30% tumor size reduction.
• Firmonertinib was generally well-tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) and no discontinuations due to TRAEs.
• Based on these results, the Company plans to initiate ALPACCA (FURMO-006), a randomized global Phase 3 study, in the second half of 2025, with 240 mg selected as the optimal dose.

Sentiment

Score: 9

Explanation: The document reports highly positive interim clinical trial data for firmonertinib, including strong efficacy (mPFS, ORR, CNS activity) and a favorable safety profile, leading to the advancement into a pivotal Phase 3 study. This indicates significant progress and potential for the drug.

Positives

• 16.0 months median progression-free survival (mPFS) with firmonertinib 240 mg by BICR in first-line patients, indicating durable systemic responses.
• 14.6 months median duration of response with firmonertinib 240 mg by BICR.
• High overall response rate (ORR) of 68.2% at the 240 mg dose level and 43.5% at the 160 mg dose level.
• Robust central nervous system (CNS) activity, with 41% (7/17) confirmed complete response (CR) and 53% (9/17) confirmed overall response (ORR) in CNS evaluable disease patients by BICR.
• Generally well-tolerated safety profile consistent with prior firmonertinib data and the EGFR-TKI class, with no Grade 4 or 5 treatment-related adverse events (TRAEs) observed.
• No treatment discontinuations due to TRAEs.
• Majority of patients treated at 240 mg remained on study after one year as of March 3, 2025.
• Advancement of firmonertinib into a global pivotal Phase 3 study (ALPACCA), designed with extensive regulatory input for potential accelerated and full approval.
• Firmonertinib 240 mg selected as the optimal dose for pivotal Phase 3 development.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
• Factors that could cause actual results to differ include risks and uncertainties described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, and other SEC filings.

Future Outlook

The Company plans to initiate ALPACCA (FURMO-006), the first randomized global Phase 3 study in first-line NSCLC patients across PACC mutations, with firmonertinib 240 mg selected as the dose for pivotal development. Enrollment of the first patient in this trial is expected in the second half of 2025. The trial design enables potential for both accelerated and full approval.

Management Comments

• "We are encouraged by the strong progression-free survival and durable systemic responses with long term firmonertinib treatment in frontline patients with EGFR PACC mutant NSCLC. Moreover, the generally well-tolerated safety profile is consistent with what has been clinically established." Bing Yao, Ph.D., Chairman and Chief Executive Officer of ArriVent.
• "We believe these Phase 1b findings support the advancement of firmonertinib towards a registration study for EGFR PACC mutant NSCLC, with potential for accelerated approval. We expect to enroll the first patient in the second half of 2025 in our randomized, global pivotal ALPACCA Phase 3 trial." Bing Yao, Ph.D.
• "Patients with PACC mutant NSCLC represent an underserved population. We believe the interim median progression free survival of 16 months observed in the FURTHER study is clinically meaningful, and together with the compelling CNS activity and favorable safety profile underscore the potential of firmonertinib to address unmet needs across patients with PACC mutations as a once daily oral, chemo-free monotherapy." Stuart Lutzker, M.D., Ph.D., Co-Founder and President of R&D of ArriVent.

Industry Context

Lung cancer is the leading cause of cancer-related deaths globally, with NSCLC accounting for approximately 85% of cases. EGFR mutations are frequent in NSCLC, and PACC mutations, representing about 12% of all EGFR mutations, are a group of uncommon EGFR mutations. Patients with uncommon EGFR mutations have significantly lower life expectancy with available therapies, representing a significant unmet medical need that firmonertinib aims to address as a once-daily oral, chemo-free monotherapy.

Comparison to Industry Standards

• The document highlights that patients with uncommon EGFR mutations, including PACC mutations, represent an "underserved population" with "significantly lower life expectancy with available therapies," indicating firmonertinib addresses a critical unmet medical need.
• The interim median progression-free survival of 16 months observed in the FURTHER study is stated to be "clinically meaningful" in this context.
• Firmonertinib's safety profile is consistent with the EGFR-TKI class, suggesting it aligns with known safety profiles for similar drugs.

Stakeholder Impact

• Shareholders: Positive clinical data and advancement to a pivotal Phase 3 study could significantly increase the company's valuation and share price, indicating strong progress towards potential commercialization.
• Patients: Firmonertinib shows promise in addressing an unmet medical need for patients with EGFR PACC mutant NSCLC, particularly those with brain metastases, offering a potential new, effective, and well-tolerated treatment option.
• Employees: Continued positive clinical development supports job security and potential growth opportunities within the company.
• Regulatory Authorities: The trial design for the pivotal Phase 3 study is based on extensive regulatory input, suggesting a clear path towards potential accelerated and full approval.

Next Steps

• Initiate ALPACCA (FURMO-006), the first randomized global Phase 3 study in first-line NSCLC in patients across PACC mutations.
• Enrollment of the first patient in the ALPACCA trial is expected in the second half of 2025.
• Host a virtual webinar on June 23, 2025, at 8 am ET to discuss the data.

Key Dates

Recommendation

Keywords

ArriVent BioPharma, AVBP, firmonertinib, NSCLC, non-small cell lung cancer, EGFR PACC mutations, Phase 1b, Phase 3, clinical trial, oncology, biopharma, drug development, progression-free survival, overall response rate, central nervous system activity, ALPACCA, FURTHER trial, targeted therapy